scholarly journals Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 3355-3363 ◽  
Author(s):  
Xiang-hui Ning ◽  
Yan-qing Gong ◽  
Shi-ming He ◽  
Teng Li ◽  
Jiang-yi Wang ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Immune Responses ◽  
Renal Cell ◽  
Clear Cell ◽  
Mrna Level ◽  
Favorable Outcome ◽  
Renal Cell Carcinomas ◽  
Tumor Tissues ◽  
Programmed Cell Death 1

PD04-07 HIGHER PD-L1 MRNA LEVEL IN CLEAR CELL RENAL CELL CARCINOMAS IS ASSOCIATED WITH A FAVORABLE OUTCOME

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Xianghui Ning ◽  
Yanqing Gong ◽  
Shiming He ◽  
Teng Li ◽  
Jiangyi Wang ◽  
...  
Keyword(s):  
Renal Cell ◽  
Clear Cell ◽  
Mrna Level ◽  
Favorable Outcome ◽  
Renal Cell Carcinomas

scholarly journals The role of B7 family molecules in hematologic malignancy

Blood ◽  
2013 ◽  
Vol 121 (5) ◽  
pp. 734-744 ◽  
Author(s):  
Paul Greaves ◽  
John G. Gribben
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Immune Responses ◽  
Hematologic Malignancy ◽  
Surface Proteins ◽  
Cell Responses ◽  
Inducible Costimulator ◽  
Programmed Cell Death 1 ◽  
B7 Family

AbstractThe B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation.

scholarly journals Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

2020 ◽  
Vol 3 (5) ◽  
pp. 176-179 ◽  
Author(s):  
Yoko Maegawa ◽  
Taigo Kato ◽  
Shinichiro Fukuhara ◽  
Hiroshi Kiuchi ◽  
Ryoichi Imamura ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Experienced Patient ◽  
Programmed Cell Death 1

scholarly journals Maprotiline Prompt the Anti-tumor Effect by Inhibiting the PD-L1 in Mice Burdened Melanoma

2021 ◽  
Author(s):  
Tiesuo Zhao ◽  
Yang Li ◽  
Miaomiao Liu ◽  
Lin Zhou ◽  
Zunge Wu ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Tumor Tissues ◽  
Programmed Cell Death 1 ◽  
Tetracyclic Antidepressant ◽  
And Migration ◽  
Cell Death Protein

Abstract Programmed cell death 1 ligand 1(PD-L1) binds with programmed cell death protein 1 (PD-1) to inhibit the responses of T cells. PD-L1 is significantly upregulated on tumor cells and blocking the PD-L1/PD-1 signal has become an important target of immunotherapy in clinic. At present, some old drugs of non-antitumor have been found that could play the effect of anti-tumor. Maprotiline, as a tetracyclic antidepressant, has been widely used for treating mental depression. Here, we study the anti-tumor effect of maprotiline by strengthening the immune response of mice. In vitro, treatment with maprotiline inhibits the proliferation and migration of B16 cells, increases the cell apoptosis. Importantly, treatment with maprotiline reduces the expression of PD-L1 in tumor tissue, prompts the ratios of CD4+ T cells, CD8+ T cells and NK cells in spleens, increases the infiltration of CD4+ and CD8+ T cells in tumor-tissues. In brief, we determine that maprotiline could prompt the anti-tumor immune response by inhibiting the PD-L1 in mice. This study may find a new inhibitor of PD-L1, which provides a new drug treated tumor in clinical.

Sign in / Sign up

Export Citation Format

Share Document